Odinwell (ODIN) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
17 Nov, 2026Executive summary
Q3 focus shifted from product development toward commercialization, with novaQS veterinary launch targeted for Q4 2026 and two global wound-care actors evaluating the platform.
After quarter-end, one global wound-care actor provided a Letter of Intent and another began an additional evaluation collaboration; a new patent application was filed in November.
Financial highlights
Q3 2026 revenue was SEK 816k vs. SEK 988k YoY; operating loss was SEK 1.442m vs. SEK 1.501m, and net loss was SEK 1.442m vs. SEK 1.400m.
Q3 EPS was -SEK 0.02 vs. -SEK 0.04 YoY; 9M revenue was SEK 2.580m vs. SEK 3.079m, operating loss SEK 4.052m vs. SEK 4.971m, and net loss SEK 4.027m vs. SEK 4.807m.
9M EPS was -SEK 0.05 vs. -SEK 0.12; cash and cash equivalents were SEK 2.957m at Sep. 30, 2026, vs. SEK 3.485m a year earlier.
Outlook and guidance
CE marking and launch of novaQS for the veterinary market remained targeted for Q4 2026; results from the horse study are expected to support product use and marketing.
Commercial focus is moving toward market entry, with further customer, distributor and strategic-partner discussions underway in Sweden and internationally.
Latest events from Odinwell
- First commercial sales mark progress toward market launch, with improved financial results.ODIN
Q2 2026 - Veterinary focus accelerates commercialization, with improved results and strong equity position.ODIN
Q1 2026 - Revenue fell, losses narrowed, and commercialization in veterinary medicine is prioritized for 2026.ODIN
Q4 2025 - Stable revenue, continued losses, strong equity, and key R&D milestones achieved.ODIN
Q3 2025 - Revenue declined and losses continued, but clinical and technical milestones were achieved.ODIN
Q2 2025 - Q3 saw narrowed losses, strong cash position, and key product development milestones reached.ODIN
Q3 2024 - Stable losses and modest revenue growth as Odinwell advances wound care sensor development.ODIN
Q2 2024 - Q1 saw stable losses, new funding, and clinical progress as Odinwell targets growth.ODIN
Q1 2025 - Improved results and strategic progress in wound care tech mark Odinwell's 2024.ODIN
Q4 2024